BeyondSpring Inc.

1.73
-0.05 (-2.81%)
At close: Feb 06, 2025, 1:51 PM
undefined%
Bid 1.7
Market Cap 69.52M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -0.4
PE Ratio (ttm) -4.31
Forward PE n/a
Analyst Buy
Ask 1.75
Volume 4,679
Avg. Volume (20D) 24,556
Open 1.71
Previous Close 1.78
Day's Range 1.70 - 1.79
52-Week Range 1.05 - 4.00
Beta undefined

About BYSI

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combinati...

Industry Biotechnology
Sector Healthcare
IPO Date Mar 9, 2017
Employees 36
Stock Exchange NASDAQ
Ticker Symbol BYSI

Analyst Forecast

According to 1 analyst ratings, the average rating for BYSI stock is "Buy." The 12-month stock price forecast is $undefined, which is a decrease of NaN% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts